Literature DB >> 21782456

Oxadiazole derivatives containing 1,4-benzodioxan as potential immunosuppressive agents against RAW264.7 cells.

Juan Sun1, Ning Cao, Xiao-Min Zhang, Yu-Shun Yang, Yan-Bin Zhang, Xiao-Ming Wang, Hai-Liang Zhu.   

Abstract

A series of oxadiazole derivatives containing 1,4-benzodioxan (4a-4s) have been first synthesized for their potential immunosuppressive activity. Among the compounds, compound 4i showed the most potent biological activity against RAW264.7 cells (inhibition=37.66±2.34% for NO overproduction and IC(50)=0.05μM for iNOS). Docking simulation was performed to position compound 4i into the iNOS structure active site to determine the probable binding model. RT-PCR experiment results demonstrated that some of these compounds possessed good immunosuppressive activity against iNOS, especially for compound 4i. Therefore, compound 4i with potent inhibitory activity may be a potential agent. Crown
Copyright © 2011. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21782456     DOI: 10.1016/j.bmc.2011.06.061

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.

Authors:  Dylan J Kahl; Kim M Hutchings; Erika Mathes Lisabeth; Andrew J Haak; Jeffrey R Leipprandt; Thomas Dexheimer; Dinesh Khanna; Pei-Suen Tsou; Phillip L Campbell; David A Fox; Bo Wen; Duxin Sun; Marc Bailie; Richard R Neubig; Scott D Larsen
Journal:  J Med Chem       Date:  2019-04-18       Impact factor: 7.446

2.  Synthesis, structure and antibacterial activity of potent DNA gyrase inhibitors: N'-benzoyl-3-(4-bromophenyl)-1H-pyrazole-5-carbohydrazide derivatives.

Authors:  Juan Sun; Peng-Cheng Lv; Yong Yin; Rong-Ju Yuan; Jian Ma; Hai-Liang Zhu
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.